TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15687321
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg L-000845704 once daily (qd)
Study: 15687321
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg L-000845704 once daily (qd)
Study: 15687321
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg L-000845704 twice daily (bid)
Study: 15687321
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of L-000845704
Study: 2025770
Drug: Compression applied
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compression applied immediately after injection
Study: 6093528
Drug: Ceftriaxone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (single dose of 250 mg)
Study: 31314045
Drug: iFR-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: iFR-guided treatment
Study: 31314045
Drug: FFR-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-guided treatment
Study: 27114196
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, adjustable to 25 mg or 100 mg based on efficacy and safety)
Study: 22645995
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg estriol as vaginal cream
Study: 20653966
Drug: Peer-led education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-led education (weekly educational programs for one month)
Study: 20969443
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using an InGaAlP diode laser, emitting light at 660 nm, 40 mW, and 4 J/cm².
Study: 27869476
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LLLT treatment).
Study: 9725475
Drug: Slow-release amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release amitriptyline formulation
Study: 8067694
Drug: 5-Fluorouracil (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil (1000 mg/m2 B.S.A. x 5 days) and Mitomycin‐C (14 mg/m2 B.S.A. 6 week intervals)
Study: 8067694
Drug: 5-Fluorouracil (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil (750 mg/m2 B.S.A. x 5 days) and a‐Interferon (5 miu/m2 B.S.A. daily x 5 then 3 times a week (TIW))
Study: 8067694
Drug: 5-Fluorouracil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil (500 mg/m2 B.S.A. x 5 days), a‐Interferon (5 miu/m2 B.S.A. x 5 days then TIW) and 13‐Cis Retinoic Acid in escalating doses daily
Study: 29733447
Drug: Verinurad 10
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 10 mg + Allopurinol 300 mg
Study: 29688628
Drug: Verinurad 10
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 10 mg
Study: 29733447
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Verinurad and Allopurinol
Study: 23653013
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (intra-muscular testosterone administered every 14 days to achieve BT levels 70-270 ng/dL)
Study: 23653013
Drug: Placebo (sesame
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sesame seed oil administered every 14 days)
Study: 20439641
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance treatment (375 mg/m² intravenously once every 3 months)
Study: 26132314
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance treatment
Study: 16295040
Drug: HS-1 (Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-1 (Barrier Cream)
Study: 16295040
Drug: HS-2 (Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-2 (Barrier Cream)
Study: 10756492
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg buserelin (BSRL) stimulation (PCOD group P-1, n = 31)
Study: 10756492
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg buserelin (BSRL) stimulation (PCOD group P-0.1, n = 12)
Study: 1504957
Drug: Concentric Circle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentric Circle (CC) palpation technique
Study: 6388898
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 0.5 to 0.75 mg/kg over 30 to 120 min.
Study: 6388898
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase (after unresponsive rt-PA treatment)
Study: 29738412
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (oCEE and tE2 combined)
Study: 18076234
Drug: Daily undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily undulating periodization (n = 10)
Study: 18076234
Drug: Weekly undulating
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly undulating periodization (n = 9)
Study: 12366698
Drug: Naltrexone (NAL)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NAL) 25 mg (Nemexin)
Study: 7641913
Drug: Low-dose GnRH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GnRH agonist (GnRH-a) and hMG therapy
Study: 7641913
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) and hMG therapy
Study: 791468
Drug: Propranolol (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (long-term therapy)
Study: 21272190
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/day MK-0916
Study: 21272190
Drug: MK-0916 (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0916 (0.5, 2, or 6 mg/day)
Study: 18001406
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily (EAC group, n = 209)
Study: 18001406
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg b.i.d. (RAC group, n = 211)
Study: 18001406
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily (EAC group)
Study: 18001406
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg b.i.d. (RAC group)
Study: 9219866
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 mg p.o.)
Study: 15013031
Drug: Pindolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (30 mg p.o.)
Study: 9219866
Drug: Betaxolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (20 mg p.o.)
Study: 8396085
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg daily for three days
Study: 8396085
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg bid for ten days
Study: 26484794
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of glimepiride and atorvastatin (once daily for 20 weeks)
Study: 26484794
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of glimepiride and atorvastatin
Study: 26484794
Drug: Co-administered glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administered glimepiride and atorvastatin (once daily for 20 weeks)
Study: 26484794
Drug: Co-administered glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administered glimepiride and atorvastatin
Study: 17686442
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and pemetrexed combination therapy; standard treatment based on phase III-study evidence; initiation of therapy as early as possible.
Study: 1729021
Drug: Intraoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous heparin administration (1000 U bolus followed by 500 U every 30 minutes)
Study: 1729021
Drug: Intraoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous heparin administration (1000 U or 1500 U initial bolus followed by continuous heparin infusion)
Study: 1729021
Drug: Intraoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous heparin administration (1000 U bolus before hip dislocation, and 500 U bolus before femoral canal preparation)
Study: 1729021
Drug: All heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All heparin groups combined
Study: 1748537
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule
Study: 3729509
Drug: Hard gelatin
Normalized name: Hard Gelatin Capsule Shell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsule
Study: 24262040
Drug: Warfarin (observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (observation group)
Study: 24262040
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant or antiplatelet medicine (control group)
Study: 11060719
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors (e.g., amprenavir, indinavir, nelfinavir, ritonavir, saquinavir)
Study: 11060719
Drug: Comparisons between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparisons between various licensed protease inhibitors
Study: 11060719
Drug: Comparisons of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparisons of protease inhibitors to other classes of potent antiretroviral drugs
Study: 11060719
Drug: Investigations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigations with new protease inhibitors
Study: 11060719
Drug: Investigations of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigations of protease inhibitor‐related toxicities
Study: 11060719
Drug: Attempts at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attempts at simplifying current dosing regimens
Study: 20205074
Drug: Olanzapine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-20 mg QD)
Study: 18555147
Drug: IV analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV analgesia with morphine (group B)
Study: 16020142
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions of time‐limited theme‐based group psychotherapy for 6 months and 50 mg sildenafil citrate orally on demand
Study: 16020142
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil citrate orally on demand for 6 months only
Study: 16020142
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions of time‐limited theme‐based group psychotherapy for 6 months
Study: 7595137
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g elemental calcium administered twice daily for 16 weeks
Study: 7595137
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for 16 weeks
Study: 382153
Drug: Domperidone suppositories
Normalized name: domperidone Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone suppositories (30 mg)
Study: 382153
Drug: Metoclopramide suppositories
Normalized name: metoclopramide Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide suppositories (10 mg)
Study: 29701801
Drug: Low vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vs. high adherence to antihypertensive medication
Study: 22433221
Drug: Docetaxel (DTX)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (DTX) alone, 75 mg/m², 8 cycles, every 3 weeks
Study: 22433221
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment groups (combined)
Study: 19281469
Drug: tolterodine-ER (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine-ER (4 mg once daily)
Study: 8066309
Drug: Verapamil (120-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120-240 mg/day)
Study: 8066309
Drug: Nitrendipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10-20 mg/day)
Study: 16116010
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block with 0.375% bupivacaine and 5 microg/mL epinephrine
Study: 12364634
Drug: 5x300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5x300 mg 4162W94 (cohort 1 and 2)
Study: 12364634
Drug: 5x100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5x100 mg 4162W94
Study: 12364634
Drug: 5x300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5x300 mg 4162W94
Study: 28953776
Drug: Duloxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine + Acetylsalicylic Acid (100 mg)
Study: 26364885
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with instructions about restricting food and fluid intake prior to radiotherapy simulation and treatment
Study: 26364885
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without instructions about restricting food and fluid intake prior to radiotherapy simulation and treatment
Study: 21247431
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 5 mg/kg intravenous bolus injection, followed by 1.5 mg/kg/h continuous intravenous infusion until 3 hours after cessation of CPB
Study: 9920070
Drug: 300 microg
Normalized name: Voglibose 300 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 microg DSG orally daily and 100 mg T enanthate, i.m., weekly
Study: 9920070
Drug: 300 microg
Normalized name: Voglibose 300 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 microg DSG and 50 mg T enanthate
Study: 9920070
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg DSG and 100 mg T enanthate
Study: 9920070
Drug: DSG (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSG (300 or 150 microg daily) alone for the first 3 weeks
Study: 9920070
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of T enanthate (50 and 100 mg weekly)
Study: 7703390
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant erythropoietin (EPO)
Study: 2641393
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg of triazolam administered sublingually
Study: 2641393
Drug: Placebo (lactulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactulose solution 66.7%)
Study: 19949
Drug: EHDP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHDP (20 mg kg‐1 day‐1)
Study: 31967979
Drug: Photobiostimulation (PBS)
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiostimulation (PBS) after implant surgery
Study: 31967979
Drug: Placebo (simulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (simulated photobiostimulation) after implant surgery
Study: 31967979
Drug: Control (implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (implant surgery only)
Study: 30146166
Drug: Monthly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly high-dose vitamin D3 supplementation (100,000 IU)
Study: 28595182
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements containing 125 mg green tea, 25 mg capsaicin and 50 mg ginger extracts
Study: 21817821
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of statin
Study: 19243207
Drug: Fed state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed state (CER 30 mg)
Study: 19243207
Drug: Fasted state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasted state (CER 30 mg)
Study: 14715180
Drug: Azimilide dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide dihydrochloride 35 mg
Study: 14715180
Drug: Azimilide dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide dihydrochloride 75 mg
Study: 14715180
Drug: Azimilide dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide dihydrochloride 125 mg
Study: 11710578
Drug: Diclofenac after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac after oral administration
Study: 11710578
Drug: Diclofenac after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac after rectal administration
Study: 11710578
Drug: Ibuprofen (internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (internal standard)
Study: 30325567
Drug: FTC/TAF 200/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TAF 200/10 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg (treatment A)
Study: 30325567
Drug: FTC/TAF 200/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TAF 200/25 mg alone (treatment C)
Study: 30325567
Drug: DRV/cobicistat (COBI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/cobicistat (COBI) 800/150 mg (treatment B)
Study: 30325567
Drug: RTV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTV and COBI boosting effects on TAF bioavailability
Study: 28609567
Drug: BI 1021958
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1021958 (60 mg single dose)
Study: 28609567
Drug: BI 1021958
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1021958 (≥60 mg single doses)
Study: 28609567
Drug: BI 1021958
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1021958 (>40 mg multiple doses)
Study: 21217530
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) group maintained normal daily activities before TKA.
Study: 19949272
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin K (K(1) and K(2)) supplementation
Study: 19949272
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin K(2) supplementation
Study: 17044661
Drug: Efonidipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efonidipine (40 mg)
Study: 17044661
Drug: Nilvadipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (2 mg)
Study: 9490088
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy protocols
Study: 2959900
Drug: Fenoterol plus
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol plus steroids
Study: 2959900
Drug: Aminophylline, IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline, IV, plus steroids and oral fenoterol
Study: 2959900
Drug: Nebulized normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized normal saline solution
Study: 29969742
Drug: uTLIF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: uTLIF with PMMA augmentation
Study: 27838680
Drug: Alternative antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative antimicrobial therapy
Study: 21570642
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g casein hydrolysate
Study: 21570642
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g casein hydrolysate
Study: 21570642
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g casein hydrolysate (control)
Study: 11101474
Drug: Fresh yogurt
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh yogurt (500 g/d for 15 days)
Study: 11101474
Drug: Heated yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated yogurt (500 g/d for 15 days)
Study: 8704064
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 20 IU AVP
Study: 8704064
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1.5 IU AVP
Study: 1288668
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physostigmine and deprenyl
Study: 20370378
Drug: Rivoglitazone 1
Normalized name: rosiglitazone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 1 mg
Study: 20370378
Drug: Rivoglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 2 mg
Study: 20370378
Drug: Rivoglitazone 3
Normalized name: Rivoglitazone
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 3 mg
Study: 18034867
Drug: Hydroxyethyl starches
Normalized name: Hydroxyethyl Starches/Hetastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starches (HES) 130/0.4, 500 ml infusion over 15 minutes